Advertisement

Pharmaceutical treatment of osteoarthritis

Published:November 19, 2022DOI:https://doi.org/10.1016/j.joca.2022.11.005

      Summary

      Objective

      To review the current state of pharmaceutical treatment recommendations for the management of osteoarthritis.

      Method

      A narrative review was drafted to describe treatment guidelines, mechanism of action, pharmacokinetics, and toxicity for nine classes of pharmaceuticals: 1) oral nonsteroidal anti-inflammatory drugs (NSAIDs), 2) topical NSAIDs, 3) COX-2 inhibitors, 4) duloxetine, 5) intra-articular corticosteroids, 6) intra-articular hyaluronic acid, 7) acetaminophen (paracetamol), 8) tramadol, and 9) capsaicin.

      Results

      In general, oral and topical NSAIDs, including COX-2 inhibitors, are strongly recommended first-line treatments for osteoarthritis due to their ability to improve pain and function but are associated with increased risks in patients with certain comorbidities (e.g., heightened cardiovascular risks). Intra-articular corticosteroid injections are generally recommended for osteoarthritis management and have relatively minor adverse effects. Other treatments, such as capsaicin, tramadol, and acetaminophen, are more controversial, and many updated guidelines offer differing recommendations.

      Conclusion

      The pharmaceutical management of osteoarthritis is a constantly evolving field. Promising treatments are emerging, and medicines that were once considered conventional (e.g., acetaminophen) are gradually becoming less acceptable based on concerns with efficacy and safety. Clinicians need to consider the latest evidence and recommendations to make an informed decision with their patients about how to optimize treatment plans for patients with knee, hip, polyarticular, or hand osteoarthritis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Osteoarthritis and Cartilage
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bannuru R.R.
        • Osani M.C.
        • Vaysbrot E.E.
        • Arden N.K.
        • Bennell K.
        • Bierma-Zeinstra S.M.A.
        • et al.
        OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.
        Osteoarthritis Cartilage. 2019; 27: 1578-1589
        • Kolasinski S.L.
        • Neogi T.
        • Hochberg M.C.
        • Oatis C.
        • Guyatt G.
        • Block J.
        • et al.
        2019 American College of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee.
        Arthritis Care Res (Hoboken). 2020; 72: 149-162
      1. American Academy of Orthopaedic Surgeons Management of Osteoarthritis of the Knee (Non-arthroplasty) Evidence-Based Clinical Practice Guideline. 2021
      2. American Academy of Orthopaedic Surgeons Management of Osteoarthritis of the Hip Evidence-Based Clinical Practice Guideline. 2017
        • Kloppenburg M.
        • Kroon F.P.B.
        • Blanco F.J.
        • Doherty M.
        • Dziedzic K.S.
        • Greibrokk E.
        • et al.
        2018 update of the EULAR recommendations for the management of hand osteoarthritis.
        Ann Rheum Dis. 2019; 78: 16
        • Bruyère O.
        • Honvo G.
        • Veronese N.
        • Arden N.K.
        • Branco J.
        • Curtis E.M.
        • et al.
        An updated algorithm recommendation for the management of knee osteoarthritis from the European society for clinical and economic aspects of Osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO).
        Semin Arthritis Rheum. 2019; 49: 337-350
        • Trelle S.
        • Reichenbach S.
        • Wandel S.
        • Hildebrand P.
        • Tschannen B.
        • Villiger P.M.
        • et al.
        Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.
        BMJ. 2011; 342: c7086
        • Fitzpatrick F.A.
        Cyclooxygenase enzymes: regulation and function.
        Curr Pharmaceut Des. 2004; 10: 577-588
        • Gierse J.K.
        • Koboldt C.M.
        • Walker M.C.
        • Seibert K.
        • Isakson P.C.
        Kinetic basis for selective inhibition of cyclo-oxygenases.
        Biochem J. 1999; 339: 607-614
        • Solomon D.H.
        NSAIDs: Pharmacology and Mechanism of Action.
        (UptoDate)2021 (Retrieved May 5, 2022, from)
        • Verbeeck R.K.
        • Blackburn J.L.
        • Loewen G.R.
        Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.
        Clin Pharmacokinet. 1983; 8: 297-331
        • Woessner K.M.
        • Castells M.
        NSAID single-drug-induced reactions.
        Immunol Allergy Clin. 2013; 33: 237-249
        • Scott P.A.
        • Kingsley G.H.
        • Smith C.M.
        • Choy E.H.
        • Scott D.L.
        Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.
        Ann Rheum Dis. 2007; 66: 1296-1304
        • Ioannidis J.P.
        • Haidich A.B.
        • Pappa M.
        • Pantazis N.
        • Kokori S.I.
        • Tektonidou M.G.
        • et al.
        Comparison of evidence of treatment effects in randomized and nonrandomized studies.
        JAMA. 2001; 286: 821-830
        • Cooper C.
        • Chapurlat R.
        • Al-Daghri N.
        • Herrero-Beaumont G.
        • Bruyère O.
        • Rannou F.
        • et al.
        Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say?.
        Drugs Aging. 2019; 36: 15-24
        • Hunter L.J.
        • Wood D.M.
        • Dargan P.I.
        The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose.
        OAEM. 2011; 3: 39-48
        • Whelton A.
        Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.
        Am J Med. 1999; 106: 13s-24s
        • Schjerning A.-M.
        • McGettigan P.
        • Gislason G.
        Cardiovascular effects and safety of (non-aspirin) NSAIDs.
        Nat Rev Cardiol. 2020; 17: 574-584
        • Varga Z.
        • Sabzwari S.R.A.
        • Vargova V.
        Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue.
        Cureus. 2017; 9 (e1144-e1144)
        • Tashiro Y.
        • Shichibe S.
        • Kato Y.
        • Hayakawa E.
        • Itoh K.
        Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.
        Biol Pharm Bull. 2001; 24: 278-283
        • Dominkus M.
        • Nicolakis M.
        • Kotz R.
        • Wilkinson F.E.
        • Kaiser R.R.
        • Chlud K.
        Comparison of tissue and plasma levels of ibuprofen after oral and topical administration.
        Arzneimittelforschung. 1996; 46: 1138-1143
        • Haroutiunian S.
        • Drennan D.A.
        • Lipman A.G.
        Topical NSAID therapy for musculoskeletal pain.
        Pain Med. 2010; 11: 535-549
        • Zeng C.
        • Wei J.
        • Persson M.S.M.
        • Sarmanova A.
        • Doherty M.
        • Xie D.
        • et al.
        Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.
        Br J Sports Med. 2018; 52: 642
        • Makris U.
        • Kohler M.
        • Fraenkel L.
        Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review.
        J Rheumatol. 2010; 37: 1236-1243
        • Vane J.R.
        • Botting R.M.
        Anti-inflammatory drugs and their mechanism of action.
        Inflamm Res. 1998; 47: S78-S87
        • Gong L.
        • Thorn C.F.
        • Bertagnolli M.M.
        • Grosser T.
        • Altman R.B.
        • Klein T.E.
        Celecoxib pathways: pharmacokinetics and pharmacodynamics.
        Pharmacogenetics Genom. 2012; 22: 310-318
        • Paulson S.K.
        • Hribar J.D.
        • Liu N.W.
        • Hajdu E.
        • Bible Jr., R.H.
        • Piergies A.
        • et al.
        Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
        Drug Metab Dispos. 2000; 28: 308-314
        • Dajani E.Z.
        • Islam K.
        Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
        J Physiol Pharmacol. 2008; 59: 117-133
        • Harris R.C.
        • Breyer M.D.
        Update on cyclooxygenase-2 inhibitors.
        Clin J Am Soc Nephrol. 2006; 1: 236
        • Pergolizzi J.V.
        • Raffa R.B.
        • Taylor Jr., R.
        • Rodriguez G.
        • Nalamachu S.
        • Langley P.
        A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.
        Pain Pract. 2013; 13: 239-252
        • Onuţu A.H.
        Duloxetine, an antidepressant with analgesic properties - a preliminary analysis.
        Rom J Anaesth Intensive Care. 2015; 22: 123-128
        • Cymbalta Label
        U.S. Food and Drug Administration.
        2004 (Retrieved June 15, 2022 from)
        • Knadler M.P.
        • Lobo E.
        • Chappell J.
        • Bergstrom R.
        Duloxetine: clinical pharmacokinetics and drug interactions.
        Clin Pharmacokinet. 2011; 50: 281-294
        • Osani M.C.
        • Bannuru R.R.
        Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis.
        Korean J Intern Med. 2019; 34: 966-973
        • Creamer P.
        Intra-articular corticosteroid injections in osteoarthritis: do they work and if so, how?.
        Ann Rheum Dis. 1997; 56: 634
        • Newton R.
        Molecular mechanisms of glucocorticoid action: what is important?.
        Thorax. 2000; 55: 603
        • Williams D.M.
        Clinical pharmacology of corticosteroids.
        Respir Care. 2018; 63: 655
        • Kraus V.B.
        • Conaghan P.G.
        • Aazami H.A.
        • Mehra P.
        • Kivitz A.J.
        • Lufkin J.
        • et al.
        Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA).
        Osteoarthritis Cartilage. 2018; 26: 34-42
        • Brown S.
        • Kumar S.
        • Sharma B.
        Intra-articular targeting of nanomaterials for the treatment of osteoarthritis.
        Acta Biomater. 2019; 93: 239-257
        • Stout A.
        • Friedly J.
        • Standaert C.J.
        Systemic absorption and side effects of locally injected glucocorticoids.
        PM&R. 2019; 11: 409-419
        • Paik J.
        • Duggan S.T.
        • Keam S.J.
        Triamcinolone acetonide extended-release: a review in osteoarthritis pain of the knee.
        Drugs. 2019; 79: 455-462
        • Habib G.S.
        Systemic effects of intra-articular corticosteroids.
        Clin Rheumatol. 2009; 28: 749-756
        • Bondy P.K.
        The adrenal cortex.
        in: Bondy P.K. Rosenberg L.E. Metabolic Control and Disease. 8th edn. Saunders, Philadelphia1980: 1427-1499
        • Kijowski R.
        Risks and benefits of intra-articular corticosteroid injection for treatment of osteoarthritis: what radiologists and patients need to know.
        Radiology. 2019; 293: 664-665
        • McAlindon T.E.
        • LaValley M.P.
        • Harvey W.F.
        • Price L.L.
        • Driban J.B.
        • Zhang M.
        • et al.
        Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial.
        JAMA. 2017; 317: 1967-1975
        • Ayhan E.
        • Kesmezacar H.
        • Akgun I.
        Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis.
        World J Orthoped. 2014; 5: 351-361
        • Rutjes A.W.
        • Jüni P.
        • da Costa B.R.
        • Trelle S.
        • Nüesch E.
        • Reichenbach S.
        Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis.
        Ann Intern Med. 2012; 157: 180-191
        • Peck J.
        • Slovek A.
        • Miro P.
        • Vij N.
        • Traube B.
        • Lee C.
        • et al.
        A comprehensive review of viscosupplementation in osteoarthritis of the knee.
        Orthop Rev (Pavia). 2021; 1325549
        • Bahrami M.H.
        • Raeissadat S.A.
        • Cheraghi M.
        • Rahimi-Dehgolan S.
        • Ebrahimpour A.
        Efficacy of single high-molecular-weight versus triple low-molecular-weight hyaluronic acid intra-articular injection among knee osteoarthritis patients.
        BMC Muscoskel Disord. 2020; 21: 550
        • Gigis I.
        • Fotiadis E.
        • Nenopoulos A.
        • Tsitas K.
        • Hatzokos I.
        Comparison of two different molecular weight intra-articular injections of hyaluronic acid for the treatment of knee osteoarthritis.
        Hippokratia. 2016; 20: 26-31
        • Wu Y.Z.
        • Huang H.T.
        • Ho C.J.
        • Shih C.L.
        • Chen C.H.
        • Cheng T.L.
        • et al.
        Molecular weight of hyaluronic acid has major influence on its efficacy and safety for viscosupplementation in hip osteoarthritis: a systematic review and meta-analysis.
        Cartilage. 2021; 13: 169s-184s
        • Hummer C.D.
        • Angst F.
        • Ngai W.
        • Whittington C.
        • Yoon S.S.
        • Duarte L.
        • et al.
        High molecular weight Intraarticular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis.
        BMC Muscoskel Disord. 2020; 21: 702
        • Fallacara A.
        • Baldini E.
        • Manfredini S.
        • Vertuani S.
        Hyaluronic acid in the third millennium.
        Polymers (Basel). 2018; 10
        • Gupta R.C.
        • Lall R.
        • Srivastava A.
        • Sinha A.
        Hyaluronic acid: molecular mechanisms and therapeutic trajectory.
        Front Vet Sci. 2019; 6: 192
        • Walker K.
        • Basehore B.M.
        • Goyal A.
        • Zito P.M.
        Hyaluronic Acid. [Updated 2021 Nov 15].
        in: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)2022 Jan (Available from: https://www.ncbi.nlm.nih.gov/books/NBK482440/)
        • Hamilton S.
        • Veiseh M.
        • Tolg C.
        • Tirona R.
        • Richardson J.
        • Brown R.
        • et al.
        Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers.
        Open Drug Metabol J. 2009; 3: 43-55
        • Balogh L.
        • Polyak A.
        • Mathe D.
        • Kiraly R.
        • Thuroczy J.
        • Terez M.
        • et al.
        Absorption, uptake and tissue affinity of high-molecular-weight hyaluronan after oral administration in rats and dogs.
        J Agric Food Chem. 2008; 56: 10582-10593
        • Jóźwiak-Bebenista M.
        • Nowak J.Z.
        Paracetamol: mechanism of action, applications and safety concern.
        Acta Pol Pharm. 2014; 71: 11-23
        • Anderson B.J.
        Paracetamol (Acetaminophen): mechanisms of action.
        Pediatric Anesthesia. 2008; 18: 915-921
        • Forrest J.A.
        • Clements J.A.
        • Prescott L.F.
        Clinical pharmacokinetics of paracetamol.
        Clin Pharmacokinet. 1982; 7: 93-107
        • Acetaminophen Label
        U.S. Food and Drug Administration.
        2015 (Retrieved June 15, 2022 from)
        • Barakat A.
        Revisiting tramadol: a multi-modal agent for pain management.
        CNS Drugs. 2019; 33: 481-501
        • Bravo L.
        • Mico J.A.
        • Berrocoso E.
        Discovery and development of tramadol for the treatment of pain.
        Expet Opin Drug Discov. 2017; 12: 1281-1291
        • Haeseler G.
        • Foadi N.
        • Ahrens J.
        • Dengler R.
        • Hecker H.
        • Leuwer M.
        Tramadol, fentanyl and sufentanil but not morphine block voltage-operated sodium channels.
        Pain. 2006; 126: 234-244
        • Hara K.
        • Minami K.
        • Sata T.
        The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
        Anesth Analg. 2005; 100: 1400-1405
        • Dayer P.
        • Desmeules J.
        • Collart L.
        Pharmacology of tramadol.
        Drugs. 1997; 53: 18-24
        • Ultram (tramadol hydrochloride) Label
        U.S. Food and Drug Administration.
        2003 (Retrieved June 15, 2022 from)
        • Gong L.
        • Stamer U.M.
        • Tzvetkov M.V.
        • Altman R.B.
        • Klein T.E.
        PharmGKB summary: tramadol pathway.
        Pharmacogenetics Genom. 2014; 24: 374-380
        • Li L.
        • Marozoff S.
        • Lu N.
        • Xie H.
        • Kopec J.A.
        • Cibere J.
        • et al.
        Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study.
        Arthritis Res Ther. 2022; 24: 85
        • Zeng C.
        • Dubreuil M.
        • LaRochelle M.R.
        • Lu N.
        • Wei J.
        • Choi H.K.
        • et al.
        Association of tramadol with all-cause mortality among patients with osteoarthritis.
        JAMA. 2019; 321: 969-982
        • Rahimi H.R.
        • Soltaninejad K.
        • Shadnia S.
        Acute tramadol poisoning and its clinical and laboratory findings.
        J Res Med Sci. 2014; 19: 855-859
        • Nakhaee S.
        • Hoyte C.
        • Dart R.C.
        • Askari M.
        • Lamarine R.J.
        • Mehrpour O.
        A review on tramadol toxicity: mechanism of action, clinical presentation, and treatment.
        Forensic Toxicol. 2021; 39: 293-310
        • Beakley B.D.
        • Kaye A.M.
        • Kaye A.D.
        Tramadol, pharmacology, side effects, and serotonin syndrome: a review.
        Pain Physician. 2015; 18: 395-400
        • Sharma S.K.
        • Vij A.S.
        • Sharma M.
        Mechanisms and clinical uses of capsaicin.
        Eur J Pharmacol. 2013; 720: 55-62
        • Anand P.
        • Bley K.
        Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch.
        Br J Anaesth. 2011; 107: 490-502
        • Babbar S.
        • Marier J.F.
        • Mouksassi M.S.
        • Beliveau M.
        • Vanhove G.F.
        • Chanda S.
        • et al.
        Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.
        Ther Drug Monit. 2009; 31: 502-510
        • McCormack P.L.
        Capsaicin dermal patch: in non-diabetic peripheral neuropathic pain.
        Drugs. 2010; 70: 1831-1842